Pacer Advisors
PTCT icon

Pacer Advisors’s PTC Therapeutics PTCT Stock Holding History

Pacer Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-235,653
Closed -$17.9M – 2353
2025
Q4 		$17.9M Sell
235,653
-268,313
-53% -$19.5M 0.05% 343
2025
Q3 		$30.9M Sell
503,966
-236,851
-32% -$12.3M 0.08% 240
2025
Q2 		$36.2M Buy
+740,817
New +$35.2M 0.09% 213
2024
Q3 		– Sell
-571
Closed -$17.5K – 2662
2024
Q2 		$17.5K Sell
571
-796
-58% -$25.8K ﹤0.01% 3452
2024
Q1 		$39.8K Buy
+1,367
New +$38.3K ﹤0.01% 3262
2021
Q2 		– Sell
-1,327
Closed -$63K – 1518
2021
Q1 		$63K Sell
1,327
-704
-35% -$41.8K ﹤0.01% 1410
2020
Q4 		$124K Sell
2,031
-102
-5% -$6.01K ﹤0.01% 1331
2020
Q3 		$100K Buy
+2,133
New +$105K ﹤0.01% 1248
2018
Q4 		– Sell
-6,384
Closed -$300K – 927
2018
Q3 		$300K Buy
+6,384
New +$264K 0.01% 953
2018
Q1 		– Sell
-1,550
Closed -$26K – 1109
2017
Q4 		$26K Buy
+1,550
New +$26.2K ﹤0.01% 1082

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Pacer Advisors's PTCT Position: Q1 2026 in Review

Pacer Advisors sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 235,653 shares — an estimated $17.9M sold.

Pacer Advisors first reported a position in PTCT in Q4 2017 and held it in 10 quarters. The position peaked at $36.2M in Q2 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Pacer Advisors reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Pacer Advisors sold 235,653 PTC Therapeutics shares in Q1 2026, an estimated $17.9M.
  • Pacer Advisors first reported a position in PTC Therapeutics in Q4 2017 and held it in 10 quarters.
  • Pacer Advisors's PTC Therapeutics position peaked at $36.2M in Q2 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.